Seed Innovations Limited Eurox -- Change of Name to Avextra
September 16 2022 - 3:03AM
RNS Non-Regulatory
TIDMSEED
Seed Innovations Limited
16 September 2022
Seed Innovations Ltd / AIM: SEED / Sector: Closed End
Investments
16 September 2022
SEED Innovations Ltd ("SEED" or, the "Company")
Eurox - Change of Name to Avextra
SEED Innovations Ltd, the AIM quoted company investing in
fast-growing and industry-leading businesses with a focus on the
medical cannabis, health and wellness space, is pleased to announce
that its portfolio company, Eurox, has rebranded to Avextra
('Avextra').
With the new name, Germany-based cannabis extracts manufacturer
Avextra wants to emphasise its clear focus on the highest quality
cannabis extracts and its commitment to the development of
evidence-based cannabis medicines. Avextra will be exhibiting at
the Expopharm Pharmacists Congress in Munich from 14-17 September
2022.
Avextra provides SEED with direct access into Germany, the
largest cannabis market in Europe today. The vertically integrated
production capabilities of Avextra cover cultivation in its
Portuguese facility, to manufacturing in Germany thanks to an
exclusive, long-term manufacturing agreement in place with an EU
GMP certified German pharmaceutical company.
ENDS
For further information on the Company please visit www.seedinnovations.co or contact:
Ed McDermott SEED Innovations E: info@seedinnovations.co
/ Ltd
Lance de Jersey
James Biddle Beaumont Cornish T: +44 (0) 207 628
/ Limited, 3396
Roland Cornish Nomad
----------------------- -------------------------------
Isabella Pierre Shard Capital Partners T: +44 (0)20 7186
/ LLP 9927
Damon Heath
----------------------- -------------------------------
Catherine St Brides Partners E: info@stbridespartners.co.uk
Leftley /Isabelle Ltd,
Morris/ Financial PR
Max Bennett
----------------------- -------------------------------
Notes
SEED Innovations is an AIM quoted investment company focused
primarily on disruptive high growth life sciences and technology
businesses particularly within the medical cannabis arena. The
Company's strategy is to identify early-stage opportunities that
have an upcoming investment catalyst and grow its portfolio in
terms of value whilst limiting the number of investee companies to
a level where relevant time can be devoted to each.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGRGDCRUBDGDL
(END) Dow Jones Newswires
September 16, 2022 04:03 ET (08:03 GMT)
Fastforward Innovations (LSE:FFWD)
Historical Stock Chart
From Apr 2024 to May 2024
Fastforward Innovations (LSE:FFWD)
Historical Stock Chart
From May 2023 to May 2024